Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study

Objectives. The aim of this study was to evaluate clinical and US-PD parameters in PsA during adalimumab treatment. Methods. A retrospective study has been conducted in forty patients affected by moderate-to-severe peripheral PsA. Clinical, laboratory, and US-PD evaluations were performed at baselin...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Teoli, A. Zangrilli, M. S. Chimenti, M. Talamonti, M. Bavetta, D. Graceffa, R. Perricone, S. Chimenti
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Clinical and Developmental Immunology
Online Access:http://dx.doi.org/10.1155/2012/823854
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849306129609261056
author M. Teoli
A. Zangrilli
M. S. Chimenti
M. Talamonti
M. Bavetta
D. Graceffa
R. Perricone
S. Chimenti
author_facet M. Teoli
A. Zangrilli
M. S. Chimenti
M. Talamonti
M. Bavetta
D. Graceffa
R. Perricone
S. Chimenti
author_sort M. Teoli
collection DOAJ
description Objectives. The aim of this study was to evaluate clinical and US-PD parameters in PsA during adalimumab treatment. Methods. A retrospective study has been conducted in forty patients affected by moderate-to-severe peripheral PsA. Clinical, laboratory, and US-PD evaluations were performed at baseline, after 4, 12, and 24 weeks of treatment. They included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), visual analogue scale (VAS), Health Assessment Questionnaire (HAQ) modified for Spondyloarthritis, Psoriasis Area Severity Index (PASI) score, the 28-joint Disease Activity Score (DAS 28), and US-PD assessment. US-PD findings were scored according to a semiquantitative scale (ranging 0–3) for synovial proliferation (SP), joint effusion (SE), bone erosions (BE), and PD. Results. Data obtained for clinical, laboratory findings and US-PD evaluation showed statistical significant improvement in all the measures performed except for BE. A significant parallel decrease in SE, SP, and PD values were demonstrated. Conclusion. This study demonstrated that US-PD is a valid technique in monitoring the response to adalimumab in moderate-to-severe PsA.
format Article
id doaj-art-397c262bcc5f4f8ebd86c1748bff1d68
institution Kabale University
issn 1740-2522
1740-2530
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Clinical and Developmental Immunology
spelling doaj-art-397c262bcc5f4f8ebd86c1748bff1d682025-08-20T03:55:11ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/823854823854Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective StudyM. Teoli0A. Zangrilli1M. S. Chimenti2M. Talamonti3M. Bavetta4D. Graceffa5R. Perricone6S. Chimenti7Department of Dermatology, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, ItalyDepartment of Dermatology, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, ItalyDepartment of Rheumatology, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, ItalyDepartment of Dermatology, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, ItalyDepartment of Dermatology, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, ItalyDepartment of Rheumatology, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, ItalyDepartment of Rheumatology, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, ItalyDepartment of Dermatology, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, ItalyObjectives. The aim of this study was to evaluate clinical and US-PD parameters in PsA during adalimumab treatment. Methods. A retrospective study has been conducted in forty patients affected by moderate-to-severe peripheral PsA. Clinical, laboratory, and US-PD evaluations were performed at baseline, after 4, 12, and 24 weeks of treatment. They included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), visual analogue scale (VAS), Health Assessment Questionnaire (HAQ) modified for Spondyloarthritis, Psoriasis Area Severity Index (PASI) score, the 28-joint Disease Activity Score (DAS 28), and US-PD assessment. US-PD findings were scored according to a semiquantitative scale (ranging 0–3) for synovial proliferation (SP), joint effusion (SE), bone erosions (BE), and PD. Results. Data obtained for clinical, laboratory findings and US-PD evaluation showed statistical significant improvement in all the measures performed except for BE. A significant parallel decrease in SE, SP, and PD values were demonstrated. Conclusion. This study demonstrated that US-PD is a valid technique in monitoring the response to adalimumab in moderate-to-severe PsA.http://dx.doi.org/10.1155/2012/823854
spellingShingle M. Teoli
A. Zangrilli
M. S. Chimenti
M. Talamonti
M. Bavetta
D. Graceffa
R. Perricone
S. Chimenti
Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
Clinical and Developmental Immunology
title Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
title_full Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
title_fullStr Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
title_full_unstemmed Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
title_short Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
title_sort evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab a retrospective study
url http://dx.doi.org/10.1155/2012/823854
work_keys_str_mv AT mteoli evaluationofclinicalandultrasonographicparametersinpsoriaticarthritispatientstreatedwithadalimumabaretrospectivestudy
AT azangrilli evaluationofclinicalandultrasonographicparametersinpsoriaticarthritispatientstreatedwithadalimumabaretrospectivestudy
AT mschimenti evaluationofclinicalandultrasonographicparametersinpsoriaticarthritispatientstreatedwithadalimumabaretrospectivestudy
AT mtalamonti evaluationofclinicalandultrasonographicparametersinpsoriaticarthritispatientstreatedwithadalimumabaretrospectivestudy
AT mbavetta evaluationofclinicalandultrasonographicparametersinpsoriaticarthritispatientstreatedwithadalimumabaretrospectivestudy
AT dgraceffa evaluationofclinicalandultrasonographicparametersinpsoriaticarthritispatientstreatedwithadalimumabaretrospectivestudy
AT rperricone evaluationofclinicalandultrasonographicparametersinpsoriaticarthritispatientstreatedwithadalimumabaretrospectivestudy
AT schimenti evaluationofclinicalandultrasonographicparametersinpsoriaticarthritispatientstreatedwithadalimumabaretrospectivestudy